TABLE 1.
Baseline characteristics of PA patients without apparent aldosteronoma
| Characteristic | (n = 36) |
|---|---|
| Age—y | 48.4 ± 12.5 |
| Male sex—no. (%) | 21 (58.3) |
| Body‐mass index—kg/m2 | 24.9 ± 3.26 |
| Fasting blood glucose— mmol/L | 5.44 ± 0.72 |
| Waist circumstance—cm | 87 ± 9 |
| Blood pressure—mmHg | |
| Systolic | 149 ± 22 |
| Diastolic | 91 ± 16 |
| Heart rate—beats/min | 80 ± 10 |
| Serum potassium—mmol/L | 3.63 ± 0.61 |
| Plasma aldosterone in supine position— ng/dL | 18.91 ± 3.85 |
| Plasma renin activity in supine position— ng/mL/h | 0.57 (0.17, 0.71) |
| Plasma aldosterone‐to‐renin ratio | 35.00 (26.00, 93.00) |
| Defined daily dose (DDD) | 1.27 (1.00, 1.93) |
| CT imaging features | |
| No change | 11(34.4) |
| Unilateral adrenal hyperplasia | 13 (40.6) |
| Bilateral adrenal hyperplasia | 8 (25.0) |
| Patients receiving (drug class) | |
| α‐1 blockers | 6 (16.7) |
| ACE inhibitors/ARBs | 13 (36.1) |
| β blocker | 5 (13.9) |
| Calcium‐channel blocker | 21 (58.3) |
| Diuretics | 4 (11.1) |
| TC—mmol/L | 4.12 ± 1.18 |
| TG—mmol/L | 2.07 ± 1.22 |
| HDL‐c—mmol/L | 1.08 ± 0.21 |
| LDL‐c—mmol/L | 2.79 ± 0.66 |
Data are mean ± SD, median with interquartile range, or n (%).The body‐mass index is the weight in kilograms divided by the square of the height in meters. The results of CT imaging did not include 4 patients who had PA recurrence after surgery.
Abbreviations: ACE, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; DDD, Defined daily dose; HDL‐c: high‐density lipid‐cholesterol; LDL‐c: low‐density lipid‐cholesterol; SD, standard deviation; TC, total cholesterol; TG, triglycerides.